UroGen Pharma

UroGen Pharma is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated.

[UroGen Pharma @UroGenPharma]

We have entered into a settlement and license agreement with Teva Pharmaceuticals, reflecting the strength of our intellectual property portfolio for low-grade upper tract urothelial cancer (LG-UTUC). Learn more: https://t.co/ddqDCw0ZYh

[UroGen Pharma @UroGenPharma]

Men are 3x more likely to be diagnosed with bladder cancer than women. This #MensHealthMonth help educate patients on the warning signs, risks, and treatment options with resources on https://t.co/VgH64GPwSv

[UroGen Pharma @UroGenPharma]

We’re excited to be at #ASCO26, sharing data and engaging with clinicians and researchers at the forefront of urologic care.

[UroGen Pharma @UroGenPharma]

Supporting the bladder cancer community is a shared effort. At UroGen, we’re proud to sponsor and participate in @BladderCancerUS’s walks nationwide alongside advocates, families, and healthcare professionals.

[UroGen Pharma @UroGenPharma]

With deep expertise across business development, portfolio strategy, and commercial operations, Timothy Simon helps shape our direction and long‑term growth, supporting patients with unmet needs. Learn more: https://t.co/hTERFk0bsZ

[UroGen Pharma @UroGenPharma]

Members of our team will participate in a virtual fireside chat for the TD Cowen 7th Annual Oncology Innovation Summit on May 26 at 10:30 AM ET. Tune in to hear our latest news and updates: https://t.co/c1wTm1wy5p

$URGN

[UroGen Pharma @UroGenPharma]

Managing recurrent LG-IR-NMIBC requires an understanding of specific risk markers. Intermediate risk is associated with a high burden of recurrence that often necessitates repeat procedures and long-term surveillance. Learn more: https://t.co/HELXalJx0O

[UroGen Pharma @UroGenPharma]

Join us for a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the Nasdaq today at 10:30-11:00 AM ET to hear our latest news and updates. https://t.co/KYXsZXwy7I

$URGN

[UroGen Pharma @UroGenPharma]

We had a great time in D.C. for #AUA26 and are looking forward to continuing our momentum before we meet again at #AUA27! If you missed us on-site, learn more and connect with us at: https://t.co/fhx0TZ1MJj

[UroGen Pharma @UroGenPharma]

President & CEO, Liz Barrett, is at #AUA26 and shares where she sees the biggest opportunity is to redefine care for uro-oncology patients.

[UroGen Pharma @UroGenPharma]

At #AUA26, our Chief Medical Officer, Mark Schoenberg, shares how UroGen is working to expand treatment options for people living with urothelial cancers and what that progress means for patients and physicians.

[UroGen Pharma @UroGenPharma]

The UroGen team is excited to be at #AUA26! Hear from CMO, Mark Schoenberg, on what he’s most excited about at this year’s meeting.

[UroGen Pharma @UroGenPharma]

We caught up with Dr. Michael Louie, UroGen’s Chief Development Officer on-site in Washington, D.C. to hear what’s energizing him at #AUA26. Watch to learn what Mike is excited about most this week.

[UroGen Pharma @UroGenPharma]

Attending #AUA26? Stop by Booth #2943! Our team members are excited to share our latest innovations as we work to discover new possibilities for #urology patients.

[UroGen Pharma @UroGenPharma]

We are pleased to share new six-month duration of response data from the Phase 3 UTOPIA study of UGN-103 (mitomycin) for intravesical solution.
Learn more about the UTOPIA trial and our results: https://t.co/MVmukFbAGy

[UroGen Pharma @UroGenPharma]

In bladder cancer, staging describes how deeply a tumor has penetrated the bladder wall. Higher stages indicate greater depth of invasion through the bladder layers, with important implications for management and monitoring. #BladderCancerAwareness

[UroGen Pharma @UroGenPharma]

Today, we announced the 36-month duration of response from the Phase 3 ENVISION trial for our treatment for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
Learn more about the results: https://t.co/N1ti1ZbyfC

[UroGen Pharma @UroGenPharma]

Join our President & CEO, Liz Barrett, and CMO, Mark Schoenberg, for an #AUA26 panel discussion on how clinicians are approaching real-world use of our medication for adults with recurrent LG-IR-NMIBC. https://t.co/W6omyautQK

[UroGen Pharma @UroGenPharma]

Our President & CEO, Liz Barrett, will be participating in a fireside chat at the Bank of America 2026 Healthcare Conference in Las Vegas on May 13 at 8:15 AM PT. Register for the webcast: https://t.co/svVZ75OoCA

[UroGen Pharma @UroGenPharma]

Today, we will report our Q1 2026 financial results. Tune in today at 10:00 AM ET to listen in on our live earnings call. https://t.co/ClOj3J4QyM

$URGN